Hengrui Medicine: Fluzoparib Capsules' Drug Marketing Authorization Application Accepted

2025-10-27 18:05:09

Hengrui Medicine announced that it recently received a "Notice of Acceptance" from the National Medical Products Administration (NMPA), accepting its drug marketing authorization application for fluzoparib capsules. Fluzoparib capsules are a poly(ADP-ribose) polymerase (PARP) inhibitor that specifically kills DRD+ tumor cells. Several PARP inhibitors have been approved for marketing worldwide, and the company has invested approximately 1.113 billion yuan in R&D related to fluzoparib capsules.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    A Republican lawmaker is seeking to halt all federal funding to New York City following the election of Zohran Mamdani as mayor
                            2025-11-09

                                    Supreme Court Pause on SNAP Benefits: Market Ripples, Policy Shock & Ticker Watch
                            2025-11-12

                                    After $2,000 Payments, Remaining Revenue to Slash National Debt
                            2025-11-16

                                    Trump Administration’s 50-Year Mortgage Gamble: What It Means for Housing, Builders and the Options Market
                            2025-11-12

                                    Gen Z expects to inherit money and assets—but their boomer parents aren’t planning on leaving anything behind
                            2025-11-11